摘要
目的比较促性腺激素释放激素激动剂（GnRH-a）与米非司酮治疗子宫肌瘤的临床疗效。方法将86例通过妇科检查、B超检查确诊的子宫肌瘤患者随机分为两组,各43例。GnRH-a组（A组）患者每次于月经来潮第1-3天在腹部前壁皮肤皮下注射GnRH-a 3.75 mg,之后每月重复注射1次,每次3.75 mg皮下注射3个月;米非司酮组（B组）患者口服米非司酮每天12.5 mg,疗程3个月。比较两组患者的疗效与不良反应发生情况。结果两组患者临床症状均有明显改善;肌瘤体积,A组缩小20%以上者38例（88.37%）,B组缩小20%以上者41例（95.35%）,差异有统计学意义（P〈0.05）。结论米非司酮较GnRH-a对子宫肌瘤有更好的治疗效果,值得临床推广。
Objective To compare the clinical efficacy of gonadotropin-releasing hormone agonist（GnRH-α） and mifepristone in the treatment of uterine fibroids.Methods 86 cases of confirmed uterine fibroid patients according to clinical symptoms /gynecological examination and B ultrasonic diagnosis were randomly divided into two groups,43 cases in each group.The GnRH-a group group A received GnRH-a subcutaneous injection in the anterior abdominal skin 3.75 mg/time in 1-3 d of menstrual cramps,after that,the injection was repeated 1 time monthly,3.75 mg/time for subcutaneous injection of 3 months;the mifepnstone group group B took mifepristone 12.5 mg/d orally for 3 months.The clinical efficacy and adverse reactions were compared between the two groups.Results The clinical symptoms of the two groups were improved significantly;the narrowing of fibroid volume by more than 20%in group A was38 cases accounting for 88.37%,while in group B,the number was 41 cases,accounting for 95.35%,which showed significant difference（P〈0.05）.Conclusion Compared with GnRH-a/mifepristone treatment for uterine fibroids has better efficacy and is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第4期40-41,共2页
China Pharmaceuticals
